Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

ProofReading European doctoral network for proofreading the proteome

Coordinator
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune, Spain
Runs
1 January 2027 to 31 December 2030
Status
Running
EU funding
€3.3m
Total cost
—
Partners
22 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101311289

What the project is doing

In the project's own words, from its summary on CORDIS.

Targeted Protein Degradation (TPD), an innovative strategy to redirect the cellular degradation machinery towards the elimination of disease-relevant proteins, has attracted enormous attention from researchers, industry and clinicians. TPD is based on the capacity of a small molecule, the degrader, to re-route the ubiquitination machinery towards a selected protein of interest to trigger its ubiquitination and degradation by the Ubiquitin Proteasomal System, via its interaction with specific E3 ubiquitin ligases.

ProofReading will bring together a diverse community, assembling the necessary multidisciplinary expertise to develop novel TPD approaches applicable to various cellular and disease contexts, facilitating the generation of degraders. ProofReading will establish an interdisciplinary, intersectoral and international research programme to drive the development of tools, degraders and innovative strategies aimed at eliminating targets involved in cancer, infection, inflammation and rare diseases.

The network comprises 10 universities, 4 research centres and 8 innovative companies, which will provide state-of-the-art training for the recruited Doctoral Candidates (DCs). This is the only doctoral network related to proteome proofreading by using TPD that combines the knowledge in all disciplines, ranging from life to physical sciences, required to develop a degrader. Interdisciplinary and intersectoral secondments will expose the DCs to different working environments.

We will organize 5 hands-on research workshops on central methodological and technical aspects of TPD and 7 courses on transferable skills, of primary importance for increasing the employability of the DCs. We will also address the important issue of mental health and well-being in science. ProofReading will train 11 researchers with specific knowledge in the cutting-edge technology of TPD, which will contribute to the generation of future drugs to treat diseases.

Topics

Who is involved

OrganisationCityCountryRole
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic BioguneDerio VizcayaSpainCoordinator
Forschungsinstitut Fur Molekulare Pathologie Gesellschaft MbhWienAustriaParticipant
Proxygen GmbHViennaAustriaAssociatedpartner
Universitat WienWienAustriaAssociatedpartner
Vrije Universiteit BrusselBruxelles / BrusselBelgiumAssociatedpartner
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandParticipant
Bruker Daltonics GmbH & Co KgBremenGermanyParticipant
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyParticipant
Philipps Universitaet MarburgMarburgGermanyParticipant
Technische Universitaet DresdenDresdenGermanyAssociatedpartner
Atlas Molecular Pharma SLDerioSpainAssociatedpartner
Fundacio Institut De Recerca Contra La Leucemia Josep CarrerasBadalonaSpainAssociatedpartner
Norarte Visual Science SLAbadiñoSpainAssociatedpartner
Oniria Therapeutics SLBarcelonaSpainAssociatedpartner
Sofia Maria Facal BelliSan Sebastián- DonostiSpainAssociatedpartner
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainAssociatedpartner
Universitat De BarcelonaBarcelonaSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Hybrigenics ServicesEvry-CourcouronnesFranceAssociatedpartner
Universite De ToulouseToulouseFranceAssociatedpartner
Universita Degli Studi Di MilanoMilanoItalyParticipant
Astrazeneca UK LimitedCambridgeUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI